| Literature DB >> 22740449 |
Yue Zhang1, Xiaomei Yan, Goro Sashida, Xinghui Zhao, Yalan Rao, Susumu Goyama, Susan P Whitman, Nicholas Zorko, Kelsie Bernot, Rajeana M Conway, David Witte, Qian-Fei Wang, Daniel G Tenen, Zhijian Xiao, Guido Marcucci, James C Mulloy, H Leighton Grimes, Michael A Caligiuri, Gang Huang.
Abstract
One mechanism for disrupting the MLL gene in myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) is through partial tandem duplication (MLL-PTD); however, the mechanism by which MLL-PTD contributes to MDS and AML development and maintenance is currently unknown. Herein, we investigated hematopoietic stem/progenitor cell (HSPC) phenotypes of Mll-PTD knock-in mice. Although HSPCs (Lin(-)Sca1(+)Kit(+) (LSK)/SLAM(+) and LSK) in Mll(PTD/WT) mice are reduced in absolute number in steady state because of increased apoptosis, they have a proliferative advantage in colony replating assays, CFU-spleen assays, and competitive transplantation assays over wild-type HSPCs. The Mll(PTD/WT)-derived phenotypic short-term (ST)-HSCs/multipotent progenitors and granulocyte/macrophage progenitors have self-renewal capability, rescuing hematopoiesis by giving rise to long-term repopulating cells in recipient mice with an unexpected myeloid differentiation blockade and lymphoid-lineage bias. However, Mll(PTD/WT) HSPCs never develop leukemia in primary or recipient mice, suggesting that additional genetic and/or epigenetic defects are necessary for full leukemogenic transformation. Thus, the Mll-PTD aberrantly alters HSPCs, enhances self-renewal, causes lineage bias, and blocks myeloid differentiation. These findings provide a framework by which we can ascertain the underlying pathogenic role of MLL-PTD in the clonal evolution of human leukemia, which should facilitate improved therapies and patient outcomes.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22740449 PMCID: PMC3412332 DOI: 10.1182/blood-2012-02-412379
Source DB: PubMed Journal: Blood ISSN: 0006-4971 Impact factor: 22.113